CDK4/6 INHIBITOR
Clinical trials for CDK4/6 INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new CDK4/6 INHIBITOR trials appear
Sign up with your email to follow new studies for CDK4/6 INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Brand or generic? study tests cheaper palbociclib for advanced breast cancer
Disease control OngoingThis study compares the effectiveness and safety of brand-name palbociclib (Ibrance) versus a local generic version in 100 Iraqi women with advanced hormone receptor-positive, HER2-negative breast cancer. The main goal is to see how long the cancer stays under control (progressio…
Matched conditions: CDK4/6 INHIBITOR
Sponsor: Al-Mustansiriyah University • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New study aims to predict cancer drug side effects before they happen
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at 100 women with breast cancer who are taking a type of drug called a CDK4/6 inhibitor. The goal is to find genetic and blood markers that can predict which patients might have severe side effects or not get enough benefit from the drug. By understanding these m…
Matched conditions: CDK4/6 INHIBITOR
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Knowledge-focused
Last updated May 26, 2026 05:46 UTC